Literature DB >> 24308680

Review of management issues in relapsed osteosarcoma.

Nataraj Vijayamurugan1, Sameer Bakhshi.   

Abstract

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever possible. Addition of chemotherapy to surgery provides survival benefit in patients not achieving second surgical remission. Even patients with multiple lung recurrences can be cured with repeated thoracotomies. Disease-free interval and complete surgical resection are the main prognostic factor for post-relapse survival.

Entities:  

Mesh:

Year:  2013        PMID: 24308680     DOI: 10.1586/14737140.2014.863453

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  11 in total

1.  A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF.

Authors:  Kexiang Zhang; Chaoyue Zhang; Li Liu; Jiahui Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 2.  Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.

Authors:  Marissa A Just; David Van Mater; Lars M Wagner
Journal:  Pediatr Blood Cancer       Date:  2021-04-24       Impact factor: 3.838

3.  Popliteal lymph node metastasis of tibial osteoblastic osteosarcoma.

Authors:  Yalın Dirik; Arda Çınar; Feridun Yumrukçal; Levent Eralp
Journal:  Int J Surg Case Rep       Date:  2014-10-13

4.  Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-κB signaling pathway.

Authors:  Yi-Jiong Li; Guo-Ping Zhang; Feng Zhao; Rui-Qi Li; Shao-Jun Liu; Zeng-Ren Zhao; Xin Wang
Journal:  Exp Ther Med       Date:  2017-12-27       Impact factor: 2.447

5.  SP1-Induced Upregulation of lncRNA LINC00514 Promotes Tumor Proliferation and Metastasis in Osteosarcoma by Regulating miR-708.

Authors:  Li-Dong Mi; Chuan-Xiu Sun; Sheng-Wei He; Guang-Yu Du
Journal:  Cancer Manag Res       Date:  2020-05-11       Impact factor: 3.989

6.  TRAF4 enhances osteosarcoma cell proliferation and invasion by Akt signaling pathway.

Authors:  Weitao Yao; Xin Wang; Qiqing Cai; Songtao Gao; Jiaqiang Wang; Peng Zhang
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

7.  LncRNA SNHG15 regulates osteosarcoma progression in vitro and in vivo via sponging miR-346 and regulating TRAF4 expression.

Authors:  Xuewu Chen; Hongguang Xu
Journal:  Open Life Sci       Date:  2020-07-03       Impact factor: 0.938

8.  Associations of chemo- and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma.

Authors:  Chujie Bai; Min Yang; Zhengfu Fan; Shu Li; Tian Gao; Zhiwei Fang
Journal:  J Exp Clin Cancer Res       Date:  2015-06-10

9.  Antisense lncRNA FOXF1-AS1 Promotes Migration and Invasion of Osteosarcoma Cells Through the FOXF1/MMP-2/-9 Pathway.

Authors:  Zhu Kun-Peng; Zhang Chun-Lin; Ma Xiao-Long
Journal:  Int J Biol Sci       Date:  2017-09-05       Impact factor: 6.580

10.  Baicalein inhibits progression of osteosarcoma cells through inactivation of the Wnt/β-catenin signaling pathway.

Authors:  Guo Dai; Di Zheng; Qianliang Wang; Jian Yang; Gaiwei Liu; Qi Song; Xiangran Sun; Chunjie Tao; Qingzhu Hu; Tian Gao; Ling Yu; Weichun Guo
Journal:  Oncotarget       Date:  2017-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.